CLOs on the Move

Paratek Pharmaceuticals

www.paratekpharm.com

 
Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that ...
  • Number of Employees: 25-100
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

bellatrx

bellatrx is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DM Clinical Research

DM Clinical Research is a clinical research company that connects pharmaceutical and research organizations to individuals seeking to power the advancement of medicine. They specialize in multiple therapeutic areas in Phase I-IV clinical trials.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.

Prism Health North Texas

PHNTX is the largest local nonprofit HIV/AIDS service organization in North Texas providing HIV care, free STI and HIV testing, transgender care, and more.

New York State Pharmacist: Century Ii

New York State Pharmacist: Century Ii is a Albany, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.